Abstract
The objective of the present work is to radiolabel a dimeric RGD peptide namely, E-c(RGDfK)2 using [99mTcN]2+ core in order to obtain a 99mTc-labeled tetrameric RGD species, which is expected to have an enhanced tumor affinity. 99mTc-labeleld [E-c(RGDfK)2]2 complex was prepared with high radiochemical purity (>95 %). Pharmacokinetic evaluation of the radiolabeled agent, carried out in C57BL/6 mice bearing melanoma tumor, demonstrated good tumor uptake within 30 min of administration (3.94 ± 0.87 % IA/g) and retention therein till 3 h post-injection (2.65 ± 0.31 % IA/g). Blocking experiment revealed the specificity of the complex towards the αvβ3 receptors in the tumor model.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
